Results 71 to 80 of about 322,587 (327)
Mutated TP53 is a marker of increased VEGF expression: analysis of 7,525 pan-cancer tissues. [PDF]
, 2020 Anti-angiogenic therapies are an important class of anti-cancer treatment drugs. However, their efficacy is limited to certain tumors and would benefit from identifying a biomarker predictive of therapeutic response.
Boichard, Amélie +2 more
core
New histone deacetylase inhibitors as potential therapeutic tools for advanced prostate carcinoma [PDF]
, 2008 The anti-epileptic drug valproic acid is also under trial as an anti-cancer agent due to its histone deacetylase (HDAC) inhibitory properties. However, the effects of valproic acid (VPA) are limited and concentrations required for exerting anti ...
Atmaca, Akin +8 more
core +1 more source
Molecular Oncology, EarlyView.Development of therapies targeting cancer‐associated fibroblasts (CAFs) necessitates preclinical model systems that faithfully represent CAF–tumor biology. We established an in vitro coculture system of patient‐derived pancreatic CAFs and tumor cell lines and demonstrated its recapitulation of primary CAF–tumor biology with single‐cell transcriptomics ...
Elysia Saputra +10 more
wiley +1 more source
A unique role for galectin-9 in angiogenesis and inflammatory arthritis
Arthritis Research & Therapy, 2018 Background Galectin-9 (Gal-9) is a mammalian lectin secreted by endothelial cells that is highly expressed in rheumatoid arthritis synovial tissues and synovial fluid.
Martin J. O’Brien +10 more
doaj +1 more source
Investigation of the marine compound spongistatin 1 links the inhibition of PKCα translocation to nonmitotic effects of tubulin antagonism in angiogenesis [PDF]
, 2009 The aims of the study were to meet the demand of new tubulin antagonists with fewer side effects by characterizing the antiangiogenic properties of the experimental compound spongistatin 1, and to elucidate nonmitotic mechanisms by which tubulin ...
Bruns, Christiane J. +7 more
core +1 more source
Dual targeting of RET and SRC synergizes in RET fusion‐positive cancer cells
Molecular Oncology, EarlyView.Despite the strong activity of selective RET tyrosine kinase inhibitors (TKIs), resistance of RET fusion‐positive (RET+) lung cancer and thyroid cancer frequently occurs and is mainly driven by RET‐independent bypass mechanisms. Son et al. show that SRC TKIs significantly inhibit PAK and AKT survival signaling and enhance the efficacy of RET TKIs in ...
Juhyeon Son +13 more
wiley +1 more source
Angiogenesis: signaling pathways and their inhibitors
Медицинская иммунология, 2019 Angiogenesis refers to the formation of new blood vessels from existing ones and is considered a crucial stage in vascular development. Two distinct types of angiogenesis have been identified: branching and non-branching angiogenesis.
Ksenia L. Markova +4 more
doaj +1 more source
The integrin-binding defective FGF2 mutants potently suppress FGF2 signalling and angiogenesis. [PDF]
, 2017 We recently found that integrin αvβ3 binds to fibroblast growth factor (FGF)-αvβ31 (FGF1), and that the integrin-binding defective FGF1 mutant (Arg-50 to glutamic acid, R50E) is defective in signalling and antagonistic to FGF1 signalling. R50E suppressed
Hamada, Yoshinosuke +10 more
core +2 more sources
Strength through diversity: how cancers thrive when clones cooperate
Molecular Oncology, EarlyView.Intratumor heterogeneity can offer direct benefits to the tumor through cooperation between different clones. In this review, Kuiken et al. discuss existing evidence for clonal cooperativity to identify overarching principles, and highlight how novel technological developments could address remaining open questions.
Marije C. Kuiken +3 more
wiley +1 more source
Pharmaceuticals, 2010 Uncontrolled neovascularization occurs in several angiogenesis-dependent diseases, including cancer. Neovascularization is tightly controlled by the balance between angiogenic growth factors and antiangiogenic agents.
Marco Rusnati +4 more
doaj +1 more source